Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ: HEPA · Real-Time Price · USD
0.3180
-0.0736 (-18.79%)
At close: May 12, 2025, 4:00 PM
0.1748
-0.1432 (-45.03%)
After-hours: May 12, 2025, 7:59 PM EDT
Hepion Pharmaceuticals Employees
Hepion Pharmaceuticals had 22 employees as of December 31, 2023. The number of employees decreased by 3 or -12.00% compared to the previous year.
Employees
22
Change (1Y)
-3
Growth (1Y)
-12.00%
Revenue / Employee
n/a
Profits / Employee
-$599,655
Market Cap
3.49M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HEPA News
- 8 hours ago - Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewsWire
- 5 days ago - Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC - GlobeNewsWire
- 2 months ago - Hepion Pharmaceuticals Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - GlobeNewsWire
- 5 months ago - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group - GlobeNewsWire
- 5 months ago - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - GlobeNewsWire
- 8 months ago - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - GlobeNewsWire
- 10 months ago - Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga